The model used the EDSS scale to define disease parameters and captures a mix of patients with both RRMS and SPMS according to the level of exacerbations suffered.
Furthermore, a distinction is made between various levels of exacerbation severity.
For the event based approach, a scale for exacerbation severity is proposed, which distinguishes two levels of exacerbation severity: (1) mild/moderate and (2) severe.
The risks of all natural deaths and non-renal deaths rose with increasing ACR quartiles, and with each doubling of ACR, with similar levels of risk exacerbation for females and males.
Positive correlations were found between the mMRC grades and concurrent levels of CRP (exacerbation: rs = 0.256, P < 0.05, the 7th day of therapy: rs = 0.289, P = 0.01) and fibrinogen (exacerbation: rs = 0.296, P < 0.01, the 7th day of therapy: rs = 0.246, P < 0.05).
None of the trials found statistically significant differences between the groups on number of exacerbations, level of control, use of rescue medication, symptoms scores, nighttime awakenings or quality of life.
However, in the trial descriptions below we restrict our focus to the following clinically most relevant ones: number of exacerbations, level of control, reliever medication use, symptom score, frequency of night-time awakening, quality of life, FEV1, hyperresponsiveness (PC20-FEV1) and PEF.
The final model was built using cohort, age, educational level, HBP, the number of general visits to the health care centre, severity level, the number of exacerbations, the impact and activity scales of the SGRQ, Beta-2 adrenergic agonist, s, xanthine treatment and the number of devices.
The clinical assessment of COPD often involves measurement of lung function parameters (e.g., FEV1) and exacerbation level of a patient to evaluate the disease progress and the therapeutic effect [ 3].
